

## Table of contents:

I.	Introduction.....	
I.1.	General definitions.....	
I.2.	Glycosylation of proteins.....	
I.2.1.	Introduction to glycosylation.....	
I.2.2.	Structure and biosynthesis of the N-glycans .....	
I.3.	Therapeutic glycoproteins .....	
I.3.1.	Therapeutic mAbs.....	
I.3.1.1.	Structure of therapeutic mAbs.....	
I.3.1.2.	Mechanisms of action of therapeutic mAbs .....	
I.3.2.	Antibody drug conjugates.....	
I.3.3.	Fc-fusion proteins .....	
I.3.4.	Therapeutic enzymes .....	
I.3.5.	Therapeutic hormones .....	
I.3.6.	Therapeutic cytokines .....	
I.3.7.	Therapeutic clotting factors .....	
I.4.	Advantages and disadvantages of therapeutic proteins .....	
I.5.	Production of therapeutic glycoproteins .....	
I.5.1.	Recombinant DNA technology.....	
I.5.2.	Modulation of glycosylation during the production of therapeutic glycoproteins: <i>glycoengineering</i> .....	
I.5.2.1.	Modulation of the glycosylation by gene silencing.....	
I.5.2.2.	Modulation of the glycosylation by choosing host cell lines .....	
I.5.2.3.	Modulation of the glycosylation by choosing culture conditions ...	
I.6.	Different glycosylation patterns change the properties of the therapeutic glycoproteins .....	

I.6.1.	Terminal sialylation and galactosylation .....
I.6.2.	Core fucosylation.....
I.6.3.	Terminal mannosylation .....
I.6.4.	Immunogenic glycan patterns.....
I.7.	Characterization of therapeutic glycoproteins .....
I.7.1.	Introduction.....
I.7.2.	Characterization of biosimilars.....
I.8.	Characterization of glycosylation.....
I.8.1.	Direct analysis of glycoforms.....
I.8.2.	Glycan mapping.....
I.8.3.	Determination of N-glycan macro- and micro-heterogeneity ....
I.8.4.	Analysis of monosaccharide content .....
	Figure 13: Chromatogram of N-glycans mixture (Z. Zhang et al. 2012). .....
I.9.	Description of techniques being used in analysis of glycans .....
I.9.1.	Glycan separation techniques .....
I.9.2.	Glycan detection techniques.....
I.9.2.1.	Derivatization and detection of glycans .....
I.9.2.2.	Fluorescence detector .....
I.9.2.3.	MS detection.....
I.9.2.4.	Detection of isomeric forms and linkage analysis.....
I.10.	Bioinformatics for glycosylation .....
II.	Aims.....
III.	Materials and methods .....
IV.	Results.....

IV.1. LC-MS analysis combined with Principal Component Analysis and Soft Independent Modelling by Class Analogy for a better detection of changes in N-glycosylation profiles of therapeutic glycoproteins .....	
IV.1.1.    Introduction.....	
IV.1.2.    Results and Discussion .....	
IV.1.3.    Conclusion .....	
IV.2. Batch-to-batch N-glycosylation Study of Infliximab, Trastuzumab, and Bevacizumab, and Stability Study of Bevacizumab .....	
IV.2.1.    Introduction.....	
IV.2.2.    Results and Discussion .....	
IV.2.3.    Conclusion .....	
IV.3. Rapid N-glycans profiling by LC-MS using free labeled approach and online solid phase extraction (article in preparation).....	
IV.3.1.    Introduction.....	
V. General conclusions and perspectives .....	
VI. References.....	
VII. Supplementary information .....	
VII.1.    Review article .....	

